The Global Autoimmune Disorders Drug Delivery Devices Market Size was valued at USD 2.7 Bn in 2020 and is expected to reach USD 7.3 Bn by 2027, growing at a CAGR of 15.0% during the forecast period.
Autoimmune disease is a type of polygenic and multifactorial, which targets different organs either specifically or systematically.
The prevalence of autoimmune diseases like rheumatoid disease is steadily increasing worldwide. Recently, many new drug delivery systems are successfully marketed to treat these diseases. However, drugs that are currently available in the market are rapidly metabolized in their free morpheme after being administered into the body, thus cleared off before getting to the target organ(s) in optimal concentrations. During the previous decade, several carrier systems in the nano-sized form are developed to take care of the sustained release of those drugs and to moderate the toxicity profile of those drugs.
Technological advancement in the field of prefilled syringes is expected to boost the growth of autoimmune disorders drug delivery devices market. Rising need for biologics and biosimilar in the pharmaceutical market due to the increasing geriatric population which drives the growth of autoimmune disorders drug delivery devices market. For instance, by 2050, the world's population aged 60 years and older is expected to around 2 billion, up from 900 million in 2015 according to WHO.
However, strict legal rules and regulations might hamper the growth of targeted market during the forecast year. Moreover, providing drug delivery devices for an untapped autoimmune disorder can create an opportunity for the growth of global market. Complications associate with the devices might act as a challenge for the market of autoimmune disorder drug delivery devices.
The Global Autoimmune Disorders Drug Delivery Devices Market Segmentation:
Based on product, the pre-filled syringes, is expected to dominate the global autoimmune disorders drug delivery devices market as prefilled syringes are safer and easier to use
Based on product, the global autoimmune disorders drug delivery devices market has been segmented into pre-filled syringes, pen injectors, vials, auto-injectors, and others. The pre-filled syringes are the dominating segment. Adoption of self-injecting parental devices and support for the pre-filled syringes from the government by providing funds also makes this segment dominating.
Based on indications, the multiple sclerosis is expected to dominate the global autoimmune disorders drug delivery devices market over the forecast period due to proactive support by the government in R&D field
Based on indications, the global autoimmune disorders drug delivery devices market has been segmented into psoriasis, multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis, systemic lupus erythematosus, and others. Multiple sclerosis is the dominating sub-segment due to the number of ongoing clinical trials focused on novel drug delivery devices using antibodies and the increasing prevalence of multiple sclerosis.
Based on end-users, hospitals segment is expected to grow at the highest CAGR during the forecast period due to increasing preference for hospital
Based on end-users, the global market is segmented into hospitals & clinics, and home care settings. Hospitals & clinics segment is witnessing significant growth during the forecast period. Hospital & clinics segment dominates the market due to favorable reimbursement and increased government support to strengthen government hospitals.
Geographically, North America accounted for the largest share of the global autoimmune disorders drug delivery devices market
North America accounted for the largest share of the market in 2020 and is expected to maintain its dominance during the forecast period. This can be attributed to the substantial investment in research and development activities carried out in the healthcare sector. This factor supports the growth of the autoimmune disorders drug delivery devices market in North America.
In addition, favorable government initiatives to support innovations in the biopharmaceutical and biosimilars industries in this region that accelerate the growth of the autoimmune disorders drug delivery devices market. Europe region is expected to be followed closely by the North America region and is expected to witness significant growth during the forecast period. This is due to an increasing number of patients and developed healthcare infrastructure in the region.
The report also provides an in-depth analysis of the global autoimmune disorders drug delivery devices market dynamics such as drivers, restraints, opportunities, and challenges
Outbreak of COVID-19 has highly affected the industries in terms of growth, economy, health, and mental well-being of every individual. In this challenging situation, every industry is trying to give the best services in terms of quality and safety. Healthcare sector has been highly affected by the COVID outbreak. However, the targeted market has not been much affected due to the corona virus.
However, the funding and focus on research and development have been distracted due to this pandemic is the restraining factor for the growth of the autoimmune disorders drug delivery system market.
The report also provides in-depth analysis of key trends in global autoimmune disorders drug delivery devices market
The report also provides in-depth analysis of recent news developments and investments
Company Profiles and Competitive Intelligence
The key players operating in the global autoimmune disorders drug delivery devices market are:
The unique insights provided by this report also includes the following:
Ask for free product review call with the author
Share your specific research requirements for a customized report
Request for due diligence and consumer centric studies
Request for study updates, segment specific and country level reports